Cervical Cancer Treatment Innovation: A Collaborative Discussion

The FDA Oncology of Excellence (OCE) in collaboration with the European Medicines Agency (EMA) presents a Conversations on Cancer program, January 14, 2025, 10:00-11:00 AM ET or 16:00-17:00 PM CET, commemorating Cervical Cancer Awareness Month titled, Cervical Cancer Treatment Innovation: A Collaborative Discussion.
Even though cervical cancer is the fourth most common cancer in women globally and is the most common cancer related cause of death in some regions, there had been minimal development of treatments for metastatic and recurrent disease until recently. In the US and Europe, while the earliest drug approvals to treat cervical cancer were granted in the 1970s, there has been limited further drug development until the last decade. Since then, an acceleration of drug development has brought anti-PD1 directed therapy and targeted therapies to patients. The year 2024 was a banner year and ongoing investigation into innovative therapeutic approaches means there is much for patients to remain hopeful about on the horizon.
Join us for an engaging discussion that will bring together key stakeholders in the fight against cervical cancer, including representatives from the patient advocacy community, academia, community oncology, the EMA and the FDA to discuss the historical path that has led us to the current treatment landscape, the impact of new therapies on individuals with cervical cancer and their families, areas of ongoing high impact research, and what the future might bring.
Discussion topics will include:
1. Raising awareness of cervical cancer
2. Historical development of cervical cancer therapy
3. Impact of new therapies on patients, their families, and friends
4. Ongoing clinical trials
5. Opportunities to drive further improvement in outcomes for individuals with cervical cancer